Allogene Therapeutics Initiates Phase 2 Trial Investigating Cemacabtagene Ansegedleucel As Part Of First Line Treatment For Patients With Large B-Cell Lymphoma Likely to Relapse
$ALLO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
- ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure Rates
- First Prospective Trial to Incorporate the Foresight Diagnostics's Investigational CLARITY™ Test to Identify Patients with LBCL Who Have Minimal Residual Disease (MRD) and are Likely to Relapse Following Standard 1L Treatment
- Unique Profile of Investigational AlloCAR T™ Products May Expand Access to CAR T within Community Cancer Centers where Most 1L Patients are Managed
- ALPHA3 Expected to Complete Enrollment in 1H 2026; BLA Submission Anticipated in 2027